Sientra (STU:S0Z0) Debt-to-Asset : 0.46 (As of Sep. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Sientra Debt-to-Asset?

Sientra's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €56.83 Mil. Sientra's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €3.87 Mil. Sientra's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2023 was €131.12 Mil. Sientra's debt to asset for the quarter that ended in Sep. 2023 was 0.46.

Sientra Debt-to-Asset Historical Data

The historical data trend for Sientra's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sientra Debt-to-Asset Chart

Sientra Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Asset

Get a 7-Day Free Trial

0.21

0.23

0.40

0.36

0.38

Sientra Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Asset	Get a 7-Day Free Trial															0.48	0.38	0.42	0.44	0.46

Competitive Comparison of Sientra's Debt-to-Asset

For the Medical Devices subindustry, Sientra's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sientra's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sientra's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Sientra's Debt-to-Asset falls into.

Sientra Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Sientra's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.721	+	57.512)	/	156.157
	=	0.38

Sientra's Debt-to-Asset for the quarter that ended in Sep. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(56.828	+	3.869)	/	131.117
	=	0.46

Sientra (STU:S0Z0) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Sientra Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Sientra's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Sientra (STU:S0Z0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sientra Inc (STU:S0Z0) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

SIEN:USA S0Z0:Germany

Address

3333 Michelson Drive, Suite 650, Irvine, CA, USA, 92612

Website

https://www.sientra.com

Sientra Inc is a part of the healthcare sector in the United States. Its business involves the provision of silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. Its operating segments are Breast Products and miraDry. The Breast Products segment focuses on sales of breast implants, tissue expanders and scar management products under the brands OPUS, AlloX2, Dermaspan, Softspan, and BIOCORNEUM. The miraDry segment focuses on sales of the miraDry System and bioTips. Geographically, the firm generates a majority of its revenue from the United States.

Sientra (STU:S0Z0) Headlines

No Headlines